Lung cancer trial aims to find optimal drug sequence for better outcomes
NCT ID NCT06486142
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study looks at the best sequence of targeted drugs (EGFR-inhibitors) for people with advanced EGFR-mutated lung cancer that cannot be cured. About 200 participants will receive different drug orders to see which improves life quality, reduces side effects, and controls tumors longer. Researchers will also analyze blood and tumor samples to find markers that guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne university hospital
RECRUITINGLund, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.